Manning & Napier Group
VRTX icon

Manning & Napier Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Manning & Napier Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$96M Sell
229,630
-7,681
-3% -$3.25M 1.1% 34
2023
Q4 		$96.6M Sell
237,311
-11,817
-5% -$4.37M 1.15% 28
2023
Q3 		$86.6M Sell
249,128
-7,499
-3% -$2.62M 1.07% 27
2023
Q2 		$90.3M Sell
256,627
-7,625
-3% -$2.57M 1.03% 32
2023
Q1 		$83.3M Sell
264,252
-7,652
-3% -$2.3M 0.97% 31
2022
Q4 		$78.5M Sell
271,904
-4,987
-2% -$1.52M 0.97% 31
2022
Q3 		$80.2M Sell
276,891
-3,116
-1% -$897K 1.05% 22
2022
Q2 		$78.9M Sell
280,007
-414,752
-60% -$111M 0.91% 34
2022
Q1 		$181M Sell
694,759
-179,213
-21% -$42.5M 1.73% 10
2021
Q4 		$192M Buy
873,972
+1,044
+0.1% +$203K 1.6% 11
2021
Q3 		$158M Sell
872,928
-24,153
-3% -$4.72M 1.36% 18
2021
Q2 		$181M Buy
897,081
+38,865
+5% +$8.13M 1.48% 14
2021
Q1 		$184M Buy
858,216
+465,772
+119% +$102M 1.57% 13
2020
Q4 		$92.7M Buy
392,444
+335,562
+590% +$77M 0.86% 37
2020
Q3 		$15.5M Buy
56,882
+2,827
+5% +$780K 0.16% 119
2020
Q2 		$15.7M Buy
54,055
+750
+1% +$203K 0.17% 119
2020
Q1 		$12.7M Sell
53,305
-165,932
-76% -$38.1M 0.15% 116
2019
Q4 		$48M Sell
219,237
-18,480
-8% -$3.74M 0.52% 57
2019
Q3 		$40.3M Sell
237,717
-145,547
-38% -$25.7M 0.45% 59
2019
Q2 		$70.3M Buy
383,264
+82,670
+28% +$14.5M 0.76% 37
2019
Q1 		$55.3M Sell
300,594
-32,214
-10% -$5.95M 0.61% 44
2018
Q4 		$55.1M Sell
332,808
-18,322
-5% -$3.17M 0.67% 44
2018
Q3 		$67.7M Sell
351,130
-10,575
-3% -$1.88M 0.67% 46
2018
Q2 		$61.5M Buy
361,705
+4,100
+1% +$636K 0.61% 49
2018
Q1 		$58.3M Sell
357,605
-544,897
-60% -$89M 0.57% 51
2017
Q4 		$135M Buy
+902,502
New +$134M 1.22% 27

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Manning & Napier Group's VRTX Position: Q1 2024 in Review

Manning & Napier Group reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q1 2024, selling an estimated $3.25M and leaving 229,630 shares worth $96M. The position accounts for 1.1% of the portfolio, ranked #34.

Manning & Napier Group first reported a position in VRTX in Q4 2017 and has held it in 26 quarters since. The position peaked at $192M in Q4 2021. 1,497 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Manning & Napier Group held 229,630 shares of Vertex Pharmaceuticals worth $96M as of Q1 2024.
  • Manning & Napier Group sold 7,681 Vertex Pharmaceuticals shares in Q1 2024, an estimated $3.25M.
  • Vertex Pharmaceuticals made up 1.1% of Manning & Napier Group's portfolio in Q1 2024, its #34 holding.
  • Manning & Napier Group first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 26 quarters since.
  • Manning & Napier Group's Vertex Pharmaceuticals position peaked at $192M in Q4 2021.
  • 1,497 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Manning & Napier Group's 13F filing for Q1 2024, filed 15 Apr 2024.